RxDoctor Payments Data

Anum Riaz, MD

Neurology · Toledo, OHNPI 1962821413

Payments from drug & device makers

$5,657in general payments, 2019–2025

Across 332 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$965
  • Neurelis, Inc.$588
  • UCB, Inc.$543
  • Eisai Inc.$383
  • Novartis$381
  • SK Life Science, Inc.$375
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,657 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$72,919
Medicare patients
362
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZonegranZonisamide15$77,343
Emgality PenGalcanezumab-Gnlm66$53,219
Nurtec OdtRimegepant Sulfate32$49,210
UbrelvyUbrogepant41$46,023
VimpatLacosamide32$40,440
Aimovig AutoinjectorErenumab-Aooe39$39,933
AptiomEslicarbazepine Acetate23$28,722
EpidiolexCannabidiol (Cbd)13$24,953
KeppraLevetiracetam13$19,964
QuliptaAtogepant17$17,948
TrileptalOxcarbazepine11$16,821
Levetiracetam412$12,501
Tegretol XrCarbamazepine14$11,848
Clobazam35$10,832
Ajovy AutoinjectorFremanezumab-Vfrm15$10,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$965$63,97158 claims
PfizerNurtec Odt$200$49,21032 claims
UCB, Inc.Vimpat, Nayzilam$543$49,06645 claims
Sunovion Pharmaceuticals Inc.Aptiom$17$28,72223 claims
Upsher-smith Laboratories LLCTopiramate$13$2,656164 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 702 neurology providers in Ohio.

Other neurology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →